Biosimilars

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

A $182,500 seizure in Quebec is just the tip of the iceberg, revealing a nationwide struggle against high-tech smuggling, drones, and prison violence.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

With a new CCO and advanced T-Body™ platform, Invenra is shifting from R&D to aggressive commercialization. Can it dominate the multispecific antibody market?

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

A strategic investment from Olayan Financing Company positions MS Pharma to dominate the MENA biologics market, fueling Saudi Arabia's Vision 2030 goals.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

The medtech firm reports a 19% revenue surge and a return to profitability, validating its new pure-play strategy focused on the surgical market.

A new drug shows major promise for a painful heart condition, with pivotal study results accepted by a top journal and a final-stage trial speeding ahead.

Biotech firm Ocubio adds commercial titan Jim Mazzo and clinical pioneer Dr. Eric Donnenfeld, signaling a major play to disrupt the ocular health market.

Henlius and Organon's POHERDY gains EC approval, set to expand access and lower costs for a critical breast cancer therapy across the European Union.

RedHill Biopharma flips a capital deficit to positive equity, driven by savvy partnerships for its drugs Talicia and Bekinda and a promising R&D pipeline.

The Health Research Foundation opens nominations for its equity award, spotlighting researchers who are closing critical health gaps for diverse communities.

EXALTA Group's new ISO 17025 accreditation for its in-house lab aims to slash development time, reflecting a broader industry push for integrated partners.

Freshly spun-off from AnaptysBio, First Tracks Biotherapeutics hits the market with a strong cash position and a pipeline aimed at celiac disease and RA.

With $108M in new funding, Terremoto Biosciences advances a novel class of drugs designed to overcome the toxicities of past cancer treatments.